The FDA has approved AstraZeneca’s Tagrisso for treating adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose disease has not progressed after radiation therapy. The drug, which generated $1.6 billion in sales in the second quarter of 2024, showed a significant reduction in disease progression or death compared to placebo in a Phase 3 trial.